Oregon Public Employees Retirement Fund Increases Position in Pfizer Inc. (PFE)

Oregon Public Employees Retirement Fund boosted its position in shares of Pfizer Inc. (NYSE:PFE) by 1.2% during the 3rd quarter, according to its most recent 13F filing with the SEC. The fund owned 1,652,936 shares of the biopharmaceutical company’s stock after purchasing an additional 19,989 shares during the quarter. Pfizer comprises about 1.0% of Oregon Public Employees Retirement Fund’s holdings, making the stock its 8th biggest holding. Oregon Public Employees Retirement Fund owned 0.10% of Pfizer worth $59,010,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently made changes to their positions in PFE. Schaper Benz & Wise Investment Counsel Inc. WI boosted its holdings in shares of Pfizer by 2.8% during the 3rd quarter. Schaper Benz & Wise Investment Counsel Inc. WI now owns 224,950 shares of the biopharmaceutical company’s stock valued at $8,031,000 after acquiring an additional 6,088 shares during the last quarter. Blackhill Capital Inc. boosted its holdings in shares of Pfizer by 9.8% during the 3rd quarter. Blackhill Capital Inc. now owns 511,201 shares of the biopharmaceutical company’s stock valued at $18,250,000 after acquiring an additional 45,773 shares during the last quarter. Boston Partners boosted its holdings in shares of Pfizer by 18.4% during the 3rd quarter. Boston Partners now owns 27,741,320 shares of the biopharmaceutical company’s stock valued at $990,365,000 after acquiring an additional 4,314,466 shares during the last quarter. Hodges Capital Management Inc. purchased a new stake in shares of Pfizer during the 3rd quarter valued at about $202,000. Finally, Prudential Financial Inc. boosted its holdings in shares of Pfizer by 30.4% during the 3rd quarter. Prudential Financial Inc. now owns 13,168,407 shares of the biopharmaceutical company’s stock valued at $470,113,000 after acquiring an additional 3,070,770 shares during the last quarter. 69.75% of the stock is currently owned by institutional investors.

In other Pfizer news, EVP Rady A. Johnson sold 8,000 shares of the firm’s stock in a transaction that occurred on Friday, December 15th. The shares were sold at an average price of $37.07, for a total transaction of $296,560.00. Following the sale, the executive vice president now owns 46,963 shares in the company, valued at approximately $1,740,918.41. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Alexander R. Mackenzie sold 6,750 shares of the firm’s stock in a transaction that occurred on Friday, December 15th. The stock was sold at an average price of $37.00, for a total transaction of $249,750.00. Following the sale, the insider now owns 103,458 shares in the company, valued at approximately $3,827,946. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 29,450 shares of company stock worth $1,065,220. 0.06% of the stock is owned by company insiders.

A number of brokerages have recently issued reports on PFE. Zacks Investment Research raised shares of Pfizer from a “hold” rating to a “buy” rating and set a $41.00 price target on the stock in a report on Wednesday. BMO Capital Markets set a $39.00 price target on shares of Pfizer and gave the company a “buy” rating in a report on Tuesday, October 31st. Deutsche Bank set a $38.00 price target on shares of Pfizer and gave the company a “buy” rating in a report on Wednesday, December 6th. Jefferies Group set a $38.00 price target on shares of Pfizer and gave the company a “neutral” rating in a report on Monday, October 16th. Finally, JPMorgan Chase & Co. set a $39.00 price target on shares of Pfizer and gave the company a “buy” rating in a report on Wednesday, November 1st. Two investment analysts have rated the stock with a sell rating, seven have issued a hold rating and thirteen have assigned a buy rating to the stock. Pfizer currently has a consensus rating of “Buy” and a consensus price target of $38.94.

Pfizer Inc. (NYSE PFE) opened at $36.99 on Friday. Pfizer Inc. has a one year low of $30.90 and a one year high of $37.37. The company has a quick ratio of 1.15, a current ratio of 1.43 and a debt-to-equity ratio of 0.56. The firm has a market cap of $220,490.00, a P/E ratio of 22.69, a PEG ratio of 2.31 and a beta of 1.01.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, October 31st. The biopharmaceutical company reported $0.67 EPS for the quarter, topping analysts’ consensus estimates of $0.65 by $0.02. Pfizer had a net margin of 18.69% and a return on equity of 25.41%. The company had revenue of $13.17 billion for the quarter, compared to analysts’ expectations of $13.17 billion. During the same quarter last year, the business earned $0.61 EPS. The firm’s revenue was up .9% compared to the same quarter last year. research analysts expect that Pfizer Inc. will post 2.59 earnings per share for the current fiscal year.

Pfizer announced that its board has approved a share repurchase program on Monday, December 18th that permits the company to buyback $10.00 billion in outstanding shares. This buyback authorization permits the biopharmaceutical company to reacquire shares of its stock through open market purchases. Stock buyback programs are often an indication that the company’s management believes its shares are undervalued.

The company also recently announced a quarterly dividend, which will be paid on Thursday, March 1st. Shareholders of record on Friday, February 2nd will be paid a dividend of $0.34 per share. This is a boost from Pfizer’s previous quarterly dividend of $0.32. The ex-dividend date is Thursday, February 1st. This represents a $1.36 dividend on an annualized basis and a yield of 3.68%. Pfizer’s dividend payout ratio (DPR) is presently 78.53%.

COPYRIGHT VIOLATION WARNING: This piece of content was posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are reading this piece of content on another domain, it was copied illegally and reposted in violation of international copyright laws. The legal version of this piece of content can be accessed at https://ledgergazette.com/2018/01/19/oregon-public-employees-retirement-fund-increases-position-in-pfizer-inc-pfe.html.

Pfizer Profile

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply